Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression

• Published in: Molecular oncology Vol. 10; no. 1; pp. 157 - 165
• Main Authors: Chang, Gregory A., Tadepalli, Jyothirmayee S., Shao, Yongzhao, Zhang, Yilong, Weiss, Sarah, Robinson, Eric, Spittle, Cindy, Furtado, Manohar, Shelton, Dawne N., Karlin-Neumann, George, Pavlick, Anna, Osman, Iman, Polsky, David
• Format: Journal Article
• Language: English
• Published: United States Elsevier B.V 01.01.2016; John Wiley & Sons, Inc; John Wiley and Sons Inc
• Subjects: Binomial distribution; Biomarker; Biomarkers; Biomarkers, Tumor - blood; BRAF; Cancer therapies; Cell-Free System; Circulating tumor DNA (ctDNA); Critical path; Data analysis; Data collection; Deoxyribonucleic acid; Disease Progression; DNA; DNA, Neoplasm - blood; Editing; GTP Phosphohydrolases - genetics; Humans; Immune checkpoint; L-Lactate Dehydrogenase - blood; Laboratories; Lactate dehydrogenase (LDH); Melanoma; Melanoma - blood; Melanoma - pathology; Membrane Proteins - genetics; Metastases; Metastasis; Mutation; Neoplasm Metastasis; NMR; NRAS; Nuclear magnetic resonance; Patients; Plasma; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins B-raf - genetics; Statistical analysis; Tumors; United States > US; NRAS; Biomarker; BRAF; Circulating tumor DNA (ctDNA); Lactate dehydrogenase (LDH); Melanoma

Melanoma lacks a clinically useful blood-based biomarker of disease activity to help guide patient management. To determine whether measurements of circulating, cell-free, tumor-associated BRAFmutant and NRASmutant DNA (ctDNA) have a higher sensitivity than LDH to detect metastatic disease prior to...